S-1: Scorpius Holdings Files for Resale of 47.4 Million Shares Following Convertible Note and Warrant Issuance

Scorpius Holdings is registering the resale of up to 47.4 million shares of common stock by existing shareholders, stemming from a recent private placement involving convertible notes and warrants.

Summary

• Scorpius Holdings has filed a registration statement for the resale of up to 47,396,667 shares of its common stock.
• These shares are being registered for resale by 3i, LP and Sabby Volatility Warrant Master Fund Ltd., referred to as the Selling Stockholders.
• The shares include 34,007,778 shares issuable upon conversion of senior secured convertible notes and 13,388,889 shares issuable upon exercise of warrants, both issued on December 6, 2024.
• The company will not receive any proceeds from the sale of these shares by the Selling Stockholders, but may receive proceeds from the cash exercise of the warrants.
• The Selling Stockholders may sell the shares at prevailing market prices or in negotiated transactions.
• The company's common stock is listed on the NYSE American under the symbol SCPX, with the last reported sale price on December 13, 2024, at $0.3001 per share.
• The company completed a private placement on December 6, 2024, issuing convertible notes and warrants for a total purchase price of $12,050,000, resulting in net proceeds of approximately $3.3 million after accounting for the repurchase of pre-funded warrants and redemption of a previous note.
• The company also completed a public offering on August 19, 2024, raising approximately $14.4 million before expenses.
• A 1-for-200 reverse stock split was effected on July 17, 2024, to increase the stock price and regain compliance with NYSE American listing requirements.

Sentiment

Score: 4

Explanation: The document highlights significant financial risks and the need for additional capital, which is concerning. While the company has taken steps to regain compliance with listing requirements, the overall outlook is uncertain, leading to a low sentiment score.

Positives

• The company successfully raised $3.3 million in net proceeds from a private placement.
• The company raised $14.4 million in a public offering in August 2024.
• The company regained compliance with NYSE American listing requirements after a reverse stock split.

Negatives

• The company will not receive any proceeds from the resale of shares by the Selling Stockholders.
• The company's stock price is low, with the last reported sale price at $0.3001 per share.
• The company has a history of needing to raise capital through the sale of securities which may dilute existing shareholders.

Risks

• The company's ability to raise additional capital is limited while the notes remain outstanding.
• The company may not be able to raise additional capital on acceptable terms or at all.
• The company's current cash is not expected to support operations beyond early January 2025 without increased revenue.
• The issuance of common stock to the Selling Stockholders may cause substantial dilution to existing stockholders.
• The company's management has broad discretion over the use of proceeds from the cash exercise of warrants.
• The company's failure to meet continued listing requirements of the NYSE American could result in delisting.
• The company is subject to risks related to its business and industry, as detailed in its filings with the SEC.

Future Outlook

The company intends to use any proceeds from the cash exercise of warrants for working capital and other general corporate purposes. The company's ability to continue operations is dependent on increasing revenue. The company is considering multiple alternatives for future financing, including additional equity financings, equipment sale leasebacks, and funding from partnerships or collaborations.

Management Comments

• Our management will have broad discretion over the use of proceeds it receives from the cash exercise of the Warrants.
• We intend to use the net proceeds, if any, received from such exercises for working capital and general corporate purposes.

Industry Context

Scorpius Holdings operates as a contract development and manufacturing organization (CDMO) in the biologics sector, providing services to biotechnology and biopharmaceutical companies. The company's focus on celland gene-based therapies and large molecule biologics aligns with current industry trends in advanced therapeutics. The company's recent financial activities, including private placements and public offerings, are common strategies for companies in this sector to fund operations and growth.

Comparison to Industry Standards

• The company's reliance on private placements and public offerings for funding is typical for early-stage biotech companies, similar to companies like Amyris and Precigen, which have also utilized these methods.
• The company's reverse stock split is a common strategy for companies facing delisting from major exchanges, similar to what companies like Cassava Sciences and Ocugen have done.
• The company's focus on cell and gene therapy manufacturing puts it in competition with larger CDMOs like Lonza and Catalent, but also smaller, specialized players like Brammer Bio and Oxford Biomedica.
• The company's net cash burn rate of $1.8 million per month, decreasing by $500,000 every three months, is a critical metric for investors to monitor, as it indicates the company's cash runway and need for additional funding. This is a common metric used to assess the financial health of biotech companies.
• The company's stock price of $0.3001 per share is significantly lower than many of its peers, indicating a higher risk profile and potential for volatility.

Related Party Transactions

• The company issued a convertible promissory note to Elusys Holdings, Inc., a company controlled by Jeffrey Wolf, the company's CEO and Chairman of the Board.
• The company entered into a Shared Services Agreement with Elusys Holdings Inc.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Shareholders may experience a decline in the value of their shares due to sales by the Selling Stockholders.
• Employees may be impacted by the company's financial instability and need for additional funding.
• Customers may be impacted by the company's ability to continue operations and provide services.
• Creditors may be impacted by the company's financial instability and need for additional funding.

Next Steps

• The company needs to obtain Stockholder Approval for the issuance of shares related to the convertible notes and warrants.
• The company needs to file a registration statement within 30 days to register the resale of the Conversion Shares and the Warrant Shares with the SEC.
• The company needs to use its commercially reasonable best efforts to have the registration statement declared effective by the SEC within 75 calendar days of the Closing Date (or 135 days if the SEC elects to review such registration statement).
• The company needs to keep such registration statement effective for one year after its effectiveness.
• The company needs to explore and secure additional financing options to support operations beyond early January 2025.

Key Dates

Keywords

common stock, resale, convertible notes, warrants, private placement, public offering, reverse stock split, biologics manufacturing, CDMO, NYSE American